TET2 and acute myeloid leukemia: DNMT3A/NPM1, DNMT3A/FLT3ITD, DNMT3A/TET2, DNMT3A/IDH1/2 mutations frequently coexist in normal-karyotype AML (NK-AML) patients [12, 54].